Skip to main content
Top
Published in: BMC Infectious Diseases 1/2020

Open Access 01-12-2020 | Human Papillomavirus | Research article

Time-trend of hospitalizations for anogenital warts in Veneto region in the HPV vaccination era: a cross sectional study (2007–2018)

Authors: S. Cocchio, G. M. Prandi, P. Furlan, C. Bertoncello, M. Fonzo, M. Saia, T. Baldovin, V. Baldo

Published in: BMC Infectious Diseases | Issue 1/2020

Login to get access

Abstract

Background

Human papillomavirus (HPV) is a common sexually transmitted pathogen and the cause of several cancers and of anogenital warts. With this study, we estimated the trend of hospitalizations for anogenital warts (AGWs) in the Veneto region (Italy) from 2007 to 2018.

Methods

The analysis included all the hospital discharge records of public and accredited private hospitals occurred in Veneto residents in the timespan 2007–2018. The ICD9-CM code 078.11 considered were those associated with condyloma acuminatum and those associated with surgical interventions for vulval/vaginal warts, penile warts anal warts. Annual total and sex- and age-specific hospitalization rates and trends were calculated and correlated with the different HPV vaccine coverage over the study period.

Results

We observed an overall reduction of hospitalization rates for AGWs: from 15.0 hospitalizations every 100,000 Veneto residents in years 2007–08 to 10.9 hospitalizations every 100,000 Veneto residents in year 2017–18 (− 37.4%; p < 0.05). Reduction has been caused by a drop in hospitalizations in females - from a rate of 20.4/100,000 in 2007–2008 to a rate of 10.8/100,000 in 2017–18 (AAPC: -7.1; 95%CI: − 10.6;-3.4); while in males, we observed a slight - but not statistically significant - increase in hospitalization rates.

Conclusion

The marked decline in hospitalization rates for AGWs in Veneto Region is probably attributable to the high coverage rates of HPV vaccination programs implemented since 2008.
Literature
1.
go back to reference Brianti P, De Flammineis E, Mercuri SR. Review of HPV-related diseases and cancers. New Microbiol. 2017;40(2):80–5.PubMed Brianti P, De Flammineis E, Mercuri SR. Review of HPV-related diseases and cancers. New Microbiol. 2017;40(2):80–5.PubMed
3.
go back to reference Lopalco PL. Spotlight on the 9-valent HPV vaccine. Drug Des Devel Ther. 2016;11:35–44.CrossRef Lopalco PL. Spotlight on the 9-valent HPV vaccine. Drug Des Devel Ther. 2016;11:35–44.CrossRef
5.
go back to reference Cappelli MG, Fortunato F, Tafuri S, Boccalini S, Bonanni P, Prato R, Martinelli D. Cervical cancer prevention: an Italian scenario between organised screening and human papillomaviruses vaccination. Eur J Cancer Care (Engl). 2018;27(5):e12905.CrossRef Cappelli MG, Fortunato F, Tafuri S, Boccalini S, Bonanni P, Prato R, Martinelli D. Cervical cancer prevention: an Italian scenario between organised screening and human papillomaviruses vaccination. Eur J Cancer Care (Engl). 2018;27(5):e12905.CrossRef
6.
go back to reference Giambi C, Declich S, Finarelli AS, Pascucci MG, Salmaso S. e il Gruppo di Sanità Pubblica del Coordinamento Interregionale della Prevenzione. Strategie vaccinali nazionali e regionali per la vaccinazione anti-HPV e primi dati di copertura vaccinale: a che punto siamo. Epicentro. https://www.epicentro.iss.it/ben/2010/novembre/2. Accessed 08 Oct 2020. Giambi C, Declich S, Finarelli AS, Pascucci MG, Salmaso S. e il Gruppo di Sanità Pubblica del Coordinamento Interregionale della Prevenzione. Strategie vaccinali nazionali e regionali per la vaccinazione anti-HPV e primi dati di copertura vaccinale: a che punto siamo. Epicentro. https://​www.​epicentro.​iss.​it/​ben/​2010/​novembre/​2. Accessed 08 Oct 2020.
7.
go back to reference Favaretti C, de Waure C, Poscia A, Sacchini D, De Vincenzo R, Bechini A, Boccalini S, Bonanni P, Zanella B, Conversano M, Battista T, Giorgino A, Russo C, Ferro A, Mennini FS, Marcellusi A, Baio G, Nardi S, Squillace A. Il vaccino anti-HPV 9-valente: report di Health. Technol Assess (HTA) QIJPH. 2017;6:5. Favaretti C, de Waure C, Poscia A, Sacchini D, De Vincenzo R, Bechini A, Boccalini S, Bonanni P, Zanella B, Conversano M, Battista T, Giorgino A, Russo C, Ferro A, Mennini FS, Marcellusi A, Baio G, Nardi S, Squillace A. Il vaccino anti-HPV 9-valente: report di Health. Technol Assess (HTA) QIJPH. 2017;6:5.
9.
go back to reference Boehmer TK, Patnaik JL, Burnite SJ, Ghosh TS, Gershman K, Vogt RL. Use of hospital discharge data to evaluate notifiable disease reporting to Colorado's electronic disease reporting system. Public Health Rep. 2011;126(1):100–6.CrossRef Boehmer TK, Patnaik JL, Burnite SJ, Ghosh TS, Gershman K, Vogt RL. Use of hospital discharge data to evaluate notifiable disease reporting to Colorado's electronic disease reporting system. Public Health Rep. 2011;126(1):100–6.CrossRef
10.
go back to reference Marra F, Ogilvie G, Colley L, Kliewer E, Marra CA. Epidemiology and costs associated with genital warts in Canada. Sex Transm Infect. 2009;85(2):111–5.CrossRef Marra F, Ogilvie G, Colley L, Kliewer E, Marra CA. Epidemiology and costs associated with genital warts in Canada. Sex Transm Infect. 2009;85(2):111–5.CrossRef
11.
go back to reference Hillemanns P, Breugelmans JG, Gieseking F, Bénard S, Lamure E, Littlewood KJ, Petry KU. Estimation of the incidence of genital warts and the cost of illness in Germany: a cross-sectional study. BMC Infect Dis. 2008;8:76.CrossRef Hillemanns P, Breugelmans JG, Gieseking F, Bénard S, Lamure E, Littlewood KJ, Petry KU. Estimation of the incidence of genital warts and the cost of illness in Germany: a cross-sectional study. BMC Infect Dis. 2008;8:76.CrossRef
12.
go back to reference Ali H, Guy RJ, Wand H, Read TR, Regan DG, Grulich AE, Fairley CK, Donovan B. Decline in in-patient treatments of genital warts among young Australians following the national HPV vaccination program. BMC Infect Dis. 2013;13:140.CrossRef Ali H, Guy RJ, Wand H, Read TR, Regan DG, Grulich AE, Fairley CK, Donovan B. Decline in in-patient treatments of genital warts among young Australians following the national HPV vaccination program. BMC Infect Dis. 2013;13:140.CrossRef
13.
go back to reference Scheinfeld N, Lehman DS. An evidence-based review of medical and surgical treatments of genital warts. Dermatol Online J. 2006;12(3):5.PubMed Scheinfeld N, Lehman DS. An evidence-based review of medical and surgical treatments of genital warts. Dermatol Online J. 2006;12(3):5.PubMed
14.
go back to reference Mariani L, Vici P, Suligoi B, Checcucci-Lisi G, Drury R. Early direct and indirect impact of quadrivalent HPV (4HPV) vaccine on genital warts: a systematic review. Adv Ther. 2015;32(1):10–30.CrossRef Mariani L, Vici P, Suligoi B, Checcucci-Lisi G, Drury R. Early direct and indirect impact of quadrivalent HPV (4HPV) vaccine on genital warts: a systematic review. Adv Ther. 2015;32(1):10–30.CrossRef
15.
go back to reference Kim HJ, Fay MP, Feuer EJ, Midthune DN. Permutation tests for joinpoint regression with applications to cancer rates. Stat Med. 2000;19(3):335–51.CrossRef Kim HJ, Fay MP, Feuer EJ, Midthune DN. Permutation tests for joinpoint regression with applications to cancer rates. Stat Med. 2000;19(3):335–51.CrossRef
16.
go back to reference Jin F, Prestage G, Kippax SC, Pell CM, Donovan B. T DJ, Kaldor J, Grulich AE. Risk factors for genital and anal warts in a prospective cohort of HIV-negative homosexual men: the HIM study. Sex Transm Dis. 2007;34(7):488–93.CrossRef Jin F, Prestage G, Kippax SC, Pell CM, Donovan B. T DJ, Kaldor J, Grulich AE. Risk factors for genital and anal warts in a prospective cohort of HIV-negative homosexual men: the HIM study. Sex Transm Dis. 2007;34(7):488–93.CrossRef
17.
go back to reference Cocchio S, Bertoncello C, Baldovin T, Buja A, Majori S, Baldo V. Self-reported genital warts among sexually active university students: a cross-sectional study. BMC Infect Dis. 2018;18:41.CrossRef Cocchio S, Bertoncello C, Baldovin T, Buja A, Majori S, Baldo V. Self-reported genital warts among sexually active university students: a cross-sectional study. BMC Infect Dis. 2018;18:41.CrossRef
18.
go back to reference Cocchio S, Baldovin T, Bertoncello C, Buja A, Furlan P, Saia M, Baldo V. Decline in hospitalization for genital warts in the Veneto region after an HPV vaccination program: an observational study. BMC Infect Dis. 2017;17(1):249.CrossRef Cocchio S, Baldovin T, Bertoncello C, Buja A, Furlan P, Saia M, Baldo V. Decline in hospitalization for genital warts in the Veneto region after an HPV vaccination program: an observational study. BMC Infect Dis. 2017;17(1):249.CrossRef
20.
go back to reference Drolet M, Bénard É, Pérez N, Brisson M. HPV vaccination impact study group. Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis. Lancet. 2019;394(10197):497–509.CrossRef Drolet M, Bénard É, Pérez N, Brisson M. HPV vaccination impact study group. Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis. Lancet. 2019;394(10197):497–509.CrossRef
21.
go back to reference Salfa MC, Ferri M, Suligoi B e la Rete Sentinella dei Centri clinici e dei Laboratori di microbiologia clinica per le Infezioni Sessualmente Trasmesse. Le Infezioni Sessualmente Trasmesse: aggiornamento dei dati dei due Sistemi di sorveglianza sentinella attivi in Italia al 31 dicembre 2018. Not Ist Sup Sanit. 2020;33(n7/8):1–39 https://wwwepicentroissit/ist/pdf/notiziario-dati-2018pdf Accessed 08 Oct 2020. Salfa MC, Ferri M, Suligoi B e la Rete Sentinella dei Centri clinici e dei Laboratori di microbiologia clinica per le Infezioni Sessualmente Trasmesse. Le Infezioni Sessualmente Trasmesse: aggiornamento dei dati dei due Sistemi di sorveglianza sentinella attivi in Italia al 31 dicembre 2018. Not Ist Sup Sanit. 2020;33(n7/8):1–39 https://​wwwepicentroissi​t/​ist/​pdf/​notiziario-dati-2018pdf Accessed 08 Oct 2020.
Metadata
Title
Time-trend of hospitalizations for anogenital warts in Veneto region in the HPV vaccination era: a cross sectional study (2007–2018)
Authors
S. Cocchio
G. M. Prandi
P. Furlan
C. Bertoncello
M. Fonzo
M. Saia
T. Baldovin
V. Baldo
Publication date
01-12-2020
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2020
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-020-05591-6

Other articles of this Issue 1/2020

BMC Infectious Diseases 1/2020 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.